

Supplementary Table 2. Univariable analysis of risk factors for overall survival and disease-free survival

Variable	Overall survival		Disease-free survival	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age (yr)		0.006		0.584
<59	1		1	
≥59	1.40 (1.10–1.79)		0.94 (0.75–1.16)	
Sphincter-saving resection		<0.001		<0.001
No	1		1	
Yes	0.54 (0.41–0.70)		0.62 (0.49–0.80)	
Initial clinical T stage		0.020		0.010
T0–2	1		1	
T3, T4	3.84 (1.23–11.99)		3.63 (1.35–9.74)	
Initial clinical N stage		0.520		0.863
cN0	1		1	
cN+	1.18 (0.72–1.92)		1.04 (0.68–1.59)	
LVi		<0.001		0.014
No	1		1	
Yes	1.98 (1.45–2.70)		2.21 (1.69–2.90)	
Pni		<0.001		<0.001
No	1		1	
Yes	2.69 (2.06–3.51)		2.76 (2.17–3.51)	
Pathologic stage		<0.001		<0.001
yp stage 0	1		1	
yp stage I	1.06 (0.64–1.75)		1.37 (0.79–2.36)	
yp stage II	2.28 (1.45–3.61)		4.08 (2.50–6.66)	
yp stage III	3.46 (2.24–5.35)		6.43 (4.00–10.34)	
Pre-nCRT mLPLN		<0.001		<0.001
No	1		1	
Yes	1.64 (1.26–2.14)		1.61 (1.26–2.05)	
Post-nCRT mLPLN		0.013		<0.001
No	1		1	
Yes	1.43 (1.07–1.90)		1.75 (1.37–2.25)	
Pathologic TRG		<0.001		<0.001
Total and near total	1		1	
Moderate and minimal and no	1.74 (1.34–2.26)		1.83 (1.44–2.33)	

HR, hazard ratio; CI, confidence interval; LVi, lymphovascular invasion; PNi, perineural invasion; nCRT, neoadjuvant chemoradiotherapy; mLPLN, lateral pelvic lymph node metastasis; TRG, tumor regression grade.